Why the study?
Do potassium channel openers offer therapeutic benefits in peripheral potassium channelopathies?
Do potassium channel openers offer therapeutic benefits in peripheral potassium channelopathies?
Potassium channel subtype-specific openers represent a potential therapeutic approach for managing peripheral potassium channelopathies, including LQT syndrome.
May support targeted K+ openers in channelopathies; leaves open confirmation in prospective trials.
Potassium channel openers (KCOs) are important tools that are often used to gain a greater understanding of K(+) channels. Agents that can induce or maintain the opening of K(+) channels also offer a therapeutic approach to controlling of cell excitability and offer a means of producing stability in biological systems. The pathogenesis of a broad range of peripheral disorders (e.g., LQT syndrome, hypokalemic periodic paralysis, hyperinsulinism in infancy and erectile dysfunction) are associated with dysfunctional K(+) channels due to mutations in genes encoding channel proteins. The therapeutic potential of KCOs in peripheral K(+) channelopathies is discussed. The identification of K(+) channel subtype-specific openers offers discrete modulation of cellular systems creating a realistic therapeutic advance in the treatment of K(+) channelopathies.
No takes yet. Share an insight, caveat, or question.
Lawson et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: